{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:20:42Z","timestamp":1759990842501},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1684\/bdc.2011.1439","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:01:59Z","timestamp":1565726519000},"page":"S117-S126","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["Gestion des effets secondaires des th\u00e9rapies cibl\u00e9es dans le cancer du rein : effets secondaires stomatologiques (mucites, \u00e9pistaxis)"],"prefix":"10.1016","volume":"98","author":[{"given":"Scarlette","family":"Agbo-Godeau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2011.1439_bib0005","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1439_bib0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1439_bib0015","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1439_bib0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1439_bib0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1439_bib0030","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1634\/theoncologist.2008-0206","article-title":"Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association?","volume":"13","author":"Aragon-Ching","year":"2008","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2011.1439_bib0035","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.revmed.2008.12.013","article-title":"Osteonecrosis of the jaw","volume":"30","author":"Pierrot-Deseilligny Despujol","year":"2009","journal-title":"Rev Med Interne"},{"key":"10.1684\/bdc.2011.1439_bib0040","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1439_bib0045","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1684\/bdc.2011.1439_bib0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"10.1684\/bdc.2011.1439_bib0055","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1439_bib0060","series-title":"Developmental therapeutics poster session","article-title":"Natural history and management of everolimus (E) induced oral ulcers (OU)","author":"Fert\u00e9","year":"2010"},{"key":"10.1684\/bdc.2011.1439_bib0065","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","article-title":"Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients","volume":"116","author":"Sonis","year":"2010","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1439_bib0070","first-page":"519","article-title":"Managing side effects of angiogenesis inhibitors in renal cell carcinoma","volume":"30","author":"Gr\u00fcnwald","year":"2007","journal-title":"Onkologie"},{"key":"10.1684\/bdc.2011.1439_bib0075","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1548-5315(11)70751-3","article-title":"Managing the side effects of sorafenib and sunitinib","volume":"3","author":"Wood","year":"2006","journal-title":"Community Oncol"},{"key":"10.1684\/bdc.2011.1439_bib0080","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1743-7563.2007.00136.x","article-title":"Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: recommendations for patient management","volume":"3","author":"Desai","year":"2007","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1684\/bdc.2011.1439_bib0085","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.gcb.2009.02.008","article-title":"Targeted biotherapies in digestive oncology: management of adverse effects","volume":"33","author":"Bouch\u00e9","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1684\/bdc.2011.1439_bib0090","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cacc.2008.01.004","article-title":"The side effects of chemotherapeutic agents","volume":"19","author":"Carr","year":"2008","journal-title":"Curr Anaesth Crit Care"},{"key":"10.1684\/bdc.2011.1439_bib0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cden.2007.10.002","article-title":"Management of oral mucositis in patients who have cancer","volume":"52","author":"Lalla","year":"2008","journal-title":"Dent Clin North Am"},{"key":"10.1684\/bdc.2011.1439_bib0100","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.22484","article-title":"Updated clinical practice guidelines for the prevention and treatment of mucositis. Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology","volume":"109","author":"Keefe","year":"2007","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1439_bib0105","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.eursup.2008.06.004","article-title":"Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma","volume":"7","author":"Roigas","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1684\/bdc.2011.1439_bib0110","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00520-004-0634-1","article-title":"Topical polyene antifungals in hematopoietic cell transplant patient: tolerability and efficacy","volume":"12","author":"Epstein","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1684\/bdc.2011.1439_bib0115","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/sj.bjc.6600824","article-title":"Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial","volume":"88","author":"Stokman","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2011.1439_bib0120","first-page":"51","article-title":"Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma","volume":"2","author":"Schwandt","year":"2009","journal-title":"OncoTargets Ther"},{"key":"10.1684\/bdc.2011.1439_bib0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1081\/CNV-120016400","article-title":"Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt & soda mouthwashes","volume":"21","author":"Dodd","year":"2003","journal-title":"Cancer Invest"},{"key":"10.1684\/bdc.2011.1439_bib0130","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1439_bib0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1359-6349(07)70110-6","article-title":"Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management","volume":"5","author":"N\u00e9grier","year":"2007","journal-title":"Eur J Cancer Suppl"},{"key":"10.1684\/bdc.2011.1439_bib0140","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"key":"10.1684\/bdc.2011.1439_bib0145","doi-asserted-by":"crossref","first-page":"773","DOI":"10.7326\/0003-4819-99-6-773","article-title":"Acyclovir prophylaxis against Herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study","volume":"99","author":"Saral","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1684\/bdc.2011.1439_bib0150","unstructured":"Afssaps. Recommandations sur la prise en charge bucco-dentaire des patients trait\u00e9s par bisphosphonates (19\/12\/2007) ; http:\/\/www.afssaps.fr\/Infos-de-securite\/Lettres-aux-professionnels-de-sante\/Recommandations-sur-la-prise-en-charge-bucco-dentaire-des-patients-traites-par-bisphosphonates\/(language)\/fre-FR"},{"key":"10.1684\/bdc.2011.1439_bib0155","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10637-008-9168-6","article-title":"Rhinitis and epistaxis in patients treated by anti-angiogenic therapy","volume":"27","author":"Pruli\u00e8re-Escabasse","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1684\/bdc.2011.1439_bib0160","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1200\/JCO.2008.19.2690","article-title":"Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies","volume":"27","author":"Steinbach","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1439_bib0165","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJMcp0807078","volume":"360","author":"Schlosser","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T23:58:49Z","timestamp":1721606329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115305300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0007455115305300"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1439","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}